Topic: kinase inhibitor

Eli Lilly headquarters

8. Eli Lilly

Eli Lilly spent nearly a quarter of its income on R&D last year, putting it near the top of its peers in percentage terms, and saw some of that spend pay off—overall, however, last year was a mixed bag for the company’s research.

Kadmon IPO crumbles after raising $75M

Unlikely IPO candidate Kadmon made it out in a tough IPO market amid swirling criticisms of its rather infamous current and former management, namely the Waksal brothers, but saw shares tumble on the open market.